Clinical Trial

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-05; most recent amendment 2024-09-03.
Status change: Not Yet Recruiting → Recruiting 2023-06-07
Trial Details
NCT Number NCT05367778
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 176 participants
Start Date 2022-06-03
Primary Completion 2025-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19